|
Patent landscape, scope, and claims summary: |
Executive summary
US Patent 8,853,412 is a broad small-molecule “Markush” composition patent centered on a substituted pyrrolidin-2-one (2-pyrrolidinone) scaffold with extensive variability across ring substituents, heteroatom linkages, terminal aryl/heteroaryl ether motifs, and stereochemical form, plus downstream coverage for (i) specific stereochemical embodiments, (ii) enumerated exemplified compounds, (iii) pharmaceutical compositions, and (iv) combination therapies and methods for treating type 2 diabetes, obesity, and dyslipidemia. The claim set, as provided, reads like a core medicinal-chemistry estate with multiple dependent claim fallbacks that narrow to defined substituent classes and specific exemplars, while also extending into formulation and combination-use claim space. The primary enforceability risk is typical of highly variable Markush claims: prior art and design-around opportunities created by the breadth of “allowed” substituent permutations, and potential indefiniteness/obviousness vulnerability in a portion of the substituent language. The key business question for any challenge, freedom-to-operate (FTO), or licensing is not whether the scaffold is protectable, but whether commercially relevant product candidates are actually within the narrow “landing zones” of claims 2, 6-9 (and their dependent restrictions), and whether any marketed compound is not only structurally adjacent but also claim-covered across the exact linkage, heteroatom, and stereochemical constraints.
US Patent 8,853,412: What claims are actually protected, at the scaffold and substitution level?
Claim architecture (from the text provided)
The independent claim 1 is a generic structure claim with broad variable definitions, followed by dependent claims 2–8 that add stereochemical and substituent restrictions. Claims 9–11 transition to specific exemplified compounds and broad composition coverage. Claims 12–31 expand into combination therapies and method-of-use claims for metabolic and cardiometabolic indications.
What is the core chemical scaffold in claim 1?
Claim 1 covers “a compound of the formula I” with these structural constraints (paraphrased into functional blocks):
A. Sidechain/connector options (X)
This controls a very specific saturation state or methylene linker identity that can matter for both binding mode and claim coverage.
B. Three aryl/heteroaryl-position substituent families (R¹a, R¹b, R¹c)
- R¹a ∈ {H, F, Cl, Br, (C1–C6)-alkyl, CN}
- R¹b ∈ {H, F, Cl, (C1–C6)-alkyl}
- R¹c ∈ {H, F, Cl, (C1–C6)-alkyl}
This is a classic breadth driver. It allows multiple halogens, CN, and alkyl at a key position.
C. Two additional substituent families on the aromatic system (R²a, R²b, R²c)
- R²a ∈ {H, F, Cl, Br, (C1–C6)-alkyl, CN, CO2R5, CONR5R5'}
- R²b ∈ {H, F, Cl, (C1–C6)-alkyl}
- R²c ∈ {H, F, Cl, (C1–C6)-alkyl}
This set includes both basic halogens and functional groups enabling polar interactions and solubility modulation.
D. Terminal ether/aminated ring arrangement (Y¹/Y², C–Z–R³–R⁴)
- One of Y¹ and Y² is N, N-oxide, or CR²d
- The other is C–Z–R³–R⁴
- R²d ∈ {H, F, Cl, (C1–C4)-alkyl}
- Z ∈ {bond, O, CO, COO, S, SO}
- R³ ∈ {bond and (CR6R6')n}
- R⁴ is a wide heteroaryl/aryl/cycloalkyl/heterocycle group with substitution limits
This block is likely the most design-around-relevant. Claim coverage depends on whether the product has (i) the required heteroatom identity (N or N-oxide) in the Y position, (ii) a permitted linker atom (Z), and (iii) a permitted R³ carbon spacer length and fluorination pattern constraints.
E. Carbon spacer constraints (R³ and R⁶/R⁶’ and n)
- n ∈ {1,2,3,4,5}
- R⁶, R⁶’ independently ∈ {H, (C1–C6)-alkyl} where alkyl is “unsubstituted or monofluorinated”
- total carbon count in (CR⁶R⁶’)n ≤ 8
This restricts the size of the “alkyl repeating unit” in the spacer. It is broad but not unlimited.
F. Stereochemical and salt/solvate forms
- “In any of its stereoisomeric forms, or a mixture … or a physiologically acceptable salt … or solvate”
Then claim 2 narrows to a specific stereochemical outcome.
Dependent claim fallbacks: how much do claims 2–8 narrow?
Claim 2
- 3-position of the pyrrolidinone ring has (R)-configuration
This is a discrete stereochemical narrowing.
Claim 3
Claim 4
- R¹a ∈ {H, F, Cl, methyl, CN}
- R¹b = H
- R¹c ∈ {H, F, methyl}
Claim 5
- R²a ∈ {H, F, Cl, methyl, CN}
- R²b = H
- R²c = H
These are meaningful for infringement posture because they reduce the “allowed” substituent set to a smaller enumerated subset, eliminating bromo and multiple alkyl/functional group categories.
Claim 6
Introduces formula Ia (subclass of claim 1) and narrows:
- R¹a ∈ {H, F, Cl, (C1–C4)-alkyl, CN}
- R¹c ∈ {H, F, (C1–C4)-alkyl}
- R²a ∈ {H, F, Cl, (C1–C4)-alkyl, CN}
- R³ ∈ {bond, (CR⁶R⁶’)n}; n ∈ {1,2,3}
- R⁶/R⁶’ ∈ {H, (C1–C2)-alkyl}; total carbon atoms in (CR⁶R⁶’)n ≤ 8
- R⁴ limited to (C1–C6)-alkyl, mono/di/trifluoro C1–C6 alkyl, O(C1–C4)alkyl, cycloalkyl, and heterocycles with oxygen constraints, and cyclic substitution limited to smaller substituents (F, C1–C4 alkyl, hydroxymethyl, acetyl, hydroxyl, oxo)
Claim 7
Back to claim 1 but with:
- X ∈ {CH2, CH2-CH2}
- R¹b = H, R²b = H, R²c = H, R²d = H
- Z ∈ {bond, O, CO, COO, S, SO}
- R³ as {bond or (CR⁶R⁶’)n}; n ∈ {1–5}
- R⁶/R⁶’ ∈ {H, methyl, ethyl, 2-fluoro-ethyl}
- R⁴ substitution restricted to F, C1–C4 alkyl, hydroxymethyl, acetyl, hydroxyl, oxo; R⁵ = C1–C4 alkyl; R⁷ ∈ {H, methyl, ethyl, hydroxy-ethyl}; R⁸/R⁸’ ∈ {C1–C4 alkyl}; R⁹ = methyl
Claim 8
Like claim 7 but tighter:
- R¹a limited as in claim 6 subset
- R¹c limited to H, F, methyl; R²a limited to H, F, C1–C4 alkyl
- R³ allows n ∈ {1–5} with R⁶/R⁶’ ∈ {H, methyl, ethyl, 2-fluoro-ethyl}
- R⁴ permitted as in claim 7 but specific ranges (C1–C6 alkyl etc.) and R⁵/R⁷/R⁸/R⁹ are constrained.
Interpretation for enforceability
Claim 1’s breadth is high; the dependent claims create multiple narrower “routes” to infringement that may be decisive if a real compound matches one of these constrained subsets (especially those controlling stereochemistry and specific ether/linker patterns like Z and X and R²b/R²c = H).
Which compounds are expressly covered by US 8,853,412 claim 9?
Claim 9 lists six (R)-configured pyrrolidin-2-one exemplars:
- (R)-3-[4-(2-Cyclopropyl-ethoxy)-phenoxy]-1-(7-fluoro-3-oxo-indan-5-yl)-pyrrolidin-2-one
- (R)-3-(6-Cyclopropylmethoxy-pyridin-3-yloxy)-1-(7-fluoro-3-oxo-indan-5-yl)-pyrrolidin-2-one
- (R)-1-(7-Fluoro-3-oxo-indan-5-yl)-3-[6-(tetrahydro-pyran-4-yloxy)-pyridin-3-yloxy]-pyrrolidin-2-one
- (R)-3-(6-Ethoxy-pyridin-3-yloxy)-1-(7-fluoro-3-oxo-indan-5-yl)-pyrrolidin-2-one
- (R)-1-(7-Fluoro-3-oxo-indan-5-yl)-3-(6-isopropoxy-pyridin-3-yloxy)-pyrrolidin-2-one
- (R)-3-(6-Cyclopropoxy-pyridin-3-yloxy)-1-(7-fluoro-3-oxo-indan-5-yl)-pyrrolidin-2-one
Business implication
These examples define the “likely commercial relevance zone” because many medicinal chemistry programs around a given scaffold optimize substitutions on (i) an indanone-like moiety with 7-fluoro-3-oxo-indan-5-yl and (ii) a pyridinyl/phenoxy ether side ring substituted with cyclopropyl/ethoxy/isopropoxy/tetrahydropyranoxy motifs. If a market candidate uses these motifs, claim 9 is the cleanest infringement anchor because it is not Markush-based.
What pharmaceutical compositions and combination therapies are claimed under US 8,853,412 claims 10–26?
Composition coverage (claims 10–13)
Claim 10
- Pharmaceutical composition comprising compound of claim 1 or salt.
Claim 11–12
- Composition additionally comprising one or more active ingredients selected from a long list spanning:
- glucose-lowering classes (insulin, GLP-1/GLP-1 analogs, DPP-IV inhibitors, SGLT-2 inhibitors, biguanides, thiazolidinediones, PPAR agonists/modulators, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, etc.)
- obesity agents and lipid/cholesterol agents
- cardiovascular and anti-RAAS agents
- various other metabolic/heart failure therapies
Claim 13
- Composition additionally metformin
How broad are the combo-enablement claims?
Claims 11 and 12 list many drug classes and named drugs, including metformin, DPP-IV inhibitors (claim 14–15), SGLT-2 inhibitors (claim 16–17), and PPAR agonists/modulators (claim 23–25). This creates:
- substantial licensing leverage for combination products
- increased freedom-to-operate complexity for any company considering multi-mechanism metabolic regimens that include the patented scaffold
Named exemplars in claims 14–25
- DPP-IV inhibitors: alogliptin, linagliptin, saxagliptin, sitagliptin, anagliptin, teneligliptin, trelagliptin, vildagliptin, gemigliptin, omarigliptin, evogliptin, dutogliptin
- SGLT-2 inhibitors: canagliflozin, dapagliflozin, remogliflozin, remogliflozin etabonate, sergliflozin, empagliflozin, ipragliflozin, tofogliflozin, luseogliflozin, ertugliflozin
- GPR40 agonists: fasiglifam (TAK-875), TUG-424, P-1736, P-11187, JTT-851, GW9508, CNX-011-67, AM-1638, AM-5262
- Lipid agents: ezetimibe; HMG-CoA reductase inhibitors include simvastatin, atorvastatin, rosuvastatin, pravastatin, fluvastatin, pitavastatin, lovastatin, mevastatin, rivastatin, cerivastatin
- PPAR: aleglitazar, muraglitazar, tesaglitazar, saroglitazar; and pioglitazone, rivoglitazone, rosiglitazone, troglitazone, lobeglitazone
- Other: acarbose
What methods of treatment are claimed under US 8,853,412 claims 27–31?
Claim 27
- Method for treating type 2 diabetes, obesity, or dyslipidemia by administering a therapeutically effective amount of claim 1 compound.
Claim 28
- Method using the composition of claim 10.
Claim 29
- Method using claim 1 compound plus at least one other useful compound.
Claim 30–31 (timing)
- claim 30: simultaneous administration
- claim 31: sequential administration
Business implication
Timing clauses often matter for design-around in combination therapy and for cross-licensing negotiations. Simultaneous vs sequential administration can determine whether a commercial regimen qualifies as infringing use, depending on the parties’ labeling and prescribing patterns. As written, the claims are structured to capture both.
How strong is the patent estate around the “Markush” scope versus the enumerated exemplars?
Strength: enumerated exemplars and narrow dependent subsets
- Claim 9 provides multiple exact (R)-specific embodiments with detailed side-chain substitutions.
- Claims 2, 3, 4, 5, 6, 7, 8 provide constrained fallback paths for infringement, reducing reliance on the broadest claim 1 permutations.
Key vulnerability: breadth and substituent variability
The claim 1 substitution language allows wide ranges:
- multiple halogens, CN, alkyl for R¹/R² positions
- broad allowance for Z linkage types and R⁴ ring systems
- stereoisomeric forms or mixtures, plus salts/solvates
This breadth can cut two ways:
- it increases the probability of covering multiple analogs in a medicinal chemistry series
- it also increases prior-art intersection and obviousness risk if the allowed permutations map onto known compounds or predictable modifications
Design-around levers visible in the claim language
A potential competitor can attempt to step outside claim language by changing:
- X linker identity (claim 3 narrows but claim 1 still allows CH2 and CH2-CH2)
- the allowed heteroatom linkage Z (claim 1 limits to bond/O/CO/COO/S/SO)
- the Y¹/Y² arrangement (requires N or N-oxide in one position unless represented by CR²d)
- stereochemistry (claim 2 targets (R) at the pyrrolidinone 3-position, but claim 1 itself is not limited)
- R³ spacer properties (n and total carbon limits in (CR⁶R⁶’)n; R⁶/R⁶’ fluorination restrictions)
What patent landscaping questions would decide licensing and litigation posture?
1) Are competitor compounds “near-miss” but outside the exact Markush limitations?
Even small changes in:
- the linkage atom Z
- the heteroatom counts in R⁴ (oxygen vs nitrogen presence)
- the ether oxygen position relative to pyridine ring
- the size and fluorination status of the spacer group (R⁶/R⁶’ and n)
can move a molecule outside literal claim scope.
2) Is the enforcement strategy built on claim 9 or claim 1?
- If a commercial product matches a claim 9 exemplar (or a direct, non-literal equivalent with close structure), the case is stronger for asserting infringement without relying on the broadest interpretation of claim 1.
- If the product is only structurally “in family,” the patentee would likely lean on claim 1’s Markush coverage and then defend the breadth against prior art and claim construction fights.
3) Do combination products increase settlement leverage?
Claims 10–26 and 27–31 create multiple routes to combination infringement:
- even if monotherapy can be designed around structurally, a combination regimen may still be covered if the patented compound is used.
- the explicit inclusion of metformin, DPP-IV inhibitors, SGLT-2 inhibitors, ezetimibe, statins, PPAR drugs, and acarbose suggests the patent is drafted to align with common clinical combination frameworks for metabolic disease.
Filing, prosecution, and expiration: what can be concluded from US 8,853,412 without external record access?
No filing date, priority date, prosecution history, claim count, or terminal disclaimer information is provided in the prompt. Without those, an accurate exclusivity timeline or an expiration date analysis cannot be produced from the claim text alone.
Key Takeaways
- Core protection is chemical scope plus Markush breadth: claim 1 covers a substituted 2-pyrrolidinone scaffold with extensive variability across aryl/heteroaryl ether substituents and linker/heteroatom patterns (X, Y¹/Y², Z, R³, R⁴, and stereoisomer/salt/solvate forms).
- Enforcement anchor is claim 9: six specific (R)-configured exemplars are listed with detailed indanone and ether-substituted pyridyl/phenoxy motifs.
- Dependent claims 2–8 narrow to defined stereochemistry and substituent subsets, creating multiple fallback infringement arguments if a product matches a particular region of the Markush space.
- Combination and method-of-use coverage is expansive: claims 10–26 and 27–31 capture compositions and administration schedules for treating type 2 diabetes, obesity, and dyslipidemia, including metformin, DPP-IV inhibitors, SGLT-2 inhibitors, PPAR agonists/modulators, statins, ezetimibe, acarbose, and GPR40 agonists, with both simultaneous and sequential administration framed in claim 30–31.
- Main competitive risk is structural and regimen-level overlap: the largest FTO exposure comes from products that are scaffold-close and marketed as monotherapy or in common glucose and lipid combination regimens.
FAQs
1) Does claim 1 cover any stereoisomer, or only (R)-forms?
Claim 1 covers “any of its stereoisomeric forms,” mixtures, and salts/solvates; dependent claim 2 targets the (R)-configuration at the pyrrolidinone 3-position.
2) What parts of the molecule are most likely to be used for design-around based on the claim language?
The Z linker set, the Y¹/Y² heteroatom requirement, the allowed R³ spacer (n and total carbon limit), and the permitted substituent sets for R¹a/R¹b/R¹c and R²a/R²b/R²c.
3) Are specific drug combinations claimed beyond general “other active ingredients useful for” language?
Yes. The claims include named agents and classes: metformin; named DPP-IV inhibitors; named SGLT-2 inhibitors; named GPR40 agonists; ezetimibe; named statins; PPAR agents; and acarbose.
4) Is infringement tied to simultaneous dosing only?
No. Claim 30 covers simultaneous administration; claim 31 covers sequential administration.
5) What is the cleanest claim path if a competitor sells a compound matching one of the listed examples?
Claim 9. Enumerated compounds reduce reliance on interpreting a broad Markush scope.
References (APA)
- US Patent 8,853,412 (claims text provided in prompt).
More… ↓
⤷ Start Trial
|
